EPS for Arrowhead Pharmaceuticals, Inc. (ARWR) Expected At $-0.15

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Logo

Analysts expect Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) to report $-0.15 EPS on December, 11.They anticipate $0.01 EPS change or 7.14 % from last quarter’s $-0.14 EPS. After having $-0.18 EPS previously, Arrowhead Pharmaceuticals, Inc.’s analysts see -16.67 % EPS growth. The stock decreased 1.84% or $0.23 during the last trading session, reaching $12.24. About 1.22M shares traded. Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) has risen 456.10% since November 14, 2017 and is uptrending. It has outperformed by 440.48% the S&P500.

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Ratings Coverage

Among 3 analysts covering Arrowhead Research (NASDAQ:ARWR), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Arrowhead Research had 5 analyst reports since May 30, 2018 according to SRatingsIntel. The stock has “Buy” rating by FBR Capital on Thursday, September 6. The firm has “Neutral” rating given on Wednesday, August 8 by FBR Capital. Cantor Fitzgerald maintained Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) rating on Monday, June 18. Cantor Fitzgerald has “Buy” rating and $1300 target. Cantor Fitzgerald maintained Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) on Wednesday, May 30 with “Buy” rating. Chardan Capital Markets maintained Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) rating on Thursday, September 6. Chardan Capital Markets has “Buy” rating and $24.5 target.

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company has market cap of $1.08 billion. The Company’s pre-clinical stage medicines include ARO-HBV to treat chronic hepatitis B virus infection; ARO-AAT for the treatment of liver disease associated with alpha-1 antitrypsin deficiency; ARO-APOC3 and ARO-ANG3 to treat hypertriglyceridemia; ARO-Lung1 for the treatment of an undisclosed pulmonary target; ARO-HIF2 to treat renal cell carcinoma; ARO-F12 for hereditary angioedema and thromboembolic disorders; and ARO-AMG1 for the treatment of an undisclosed genetically validated cardiovascular target. It currently has negative earnings. Arrowhead Pharmaceuticals, Inc. has collaboration and license agreement with Amgen, Inc.

More important recent Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) news were published by: Streetinsider.com which released: “Arrowhead Pharma (ARWR) Presents Late-Breaking Preliminary Clinical Data on ARO-HBV at Liver Meeting” on November 09, 2018, also Seekingalpha.com published article titled: “Key events next week – healthcare”, Fool.com published: “Here’s Why Arrowhead Pharmaceuticals Dropped 33.6% in October” on November 07, 2018. More interesting news about Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) was released by: Seekingalpha.com and their article: “Arrowhead Pharmaceuticals: A Steal Under $15?” with publication date: October 29, 2018.

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.